News
OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors
First clinical trial to test the safety and efficacy of a novel first-in-class targeted therapy (small-molecule prodrug) that selectively releases a potent DNA alkylating agent …
OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)
First Clinical Trial to Test the Safety and Preliminary Activity of Passive Immunotherapy based on a Monoclonal Antibody targeting Globo H, a glycolipid antigen found …
OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.
Taipei, Taiwan, December 22, 2017 6:00pm – OBI Pharma, Inc. (TPEx:4174), a Taiwan biopharma company specializing in the development of novel first-in-class cancer therapeutics that …
OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Study finds OBI-3424 exerts profound in vivo efficacy and safety against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) expressing AKR1C3. Taipei, Taiwan, …
OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Poster presentation to reveal data regarding in vivo efficacy against patient-derived xenografts (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) Taipei, Taiwan, October 24, 2017 …